The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

Share Price Information for Belluscura (BELL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.00
Bid: 7.50
Ask: 8.50
Change: 0.00 (0.00%)
Spread: 1.00 (13.333%)
Open: 8.00
High: 0.00
Low: 0.00
Prev. Close: 8.00
BELL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution Agreement & New VP North America

13 Feb 2024 07:00

RNS Number : 8870C
Belluscura PLC
13 February 2024
 

13 February 2024

 

Belluscura plc

("Belluscura" or the "Company")

 

Belluscura announces implementation of distribution agreement with Sunset HealthCare Solutions

New Vice President of North American Sales

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces a new partnership with Sunset HealthCare Solutions ("Sunset Healthcare") and the promotion of Konstantin Grey to Vice President of North American Sales.

 

Sunset HealthCare is a Chicago-based manufacturer and distributor of Home Medical Equipment ("HME") supplies offering an extensive range of quality HME products, innovative solutions and specialised product support. It partners with over 1,600 healthcare businesses, serving all of the United States alongside key international accounts. Sunset Healthcare has a network of sales representatives extending across the US and in 150 countries around the globe.

 

Under the distribution agreement, Sunset HealthCare will offer the X-PLOR® portable oxygen concentrator ("POC") to over 1,600 customers. It is intended that the agreement will be extended to also include distribution of the award winning DISCOV-R? POC in Q2 2024 when the product becomes available to Durable Medical Equipment ("DME") suppliers.

 

Belluscura also announces that Konstantin Grey has been appointed Vice President of North American Sales. Having joined Belluscura in July 2023, Konstantin has been responsible for the creation and launch of Belluscura's direct to consumer sales force and website, which has seen strong growth in sales and gross margins since its launch last year. He also successfully launched our unique direct to consumer leasing program and has been instrumental in driving this new partnership with Sunset HealthCare, as well as a healthy pipeline of further opportunities. Konstantin has 15 years of experience in the DME industry, including having founded and subsequently sold his own DME company.

 

Robert Rauker, Chief Executive Officer, Belluscura plc, said:

 

"We welcome the new partnership with Sunset HealthCare Solutions, which will provide over 1,600 healthcare businesses with access to our innovative products through a trusted, industry leader. This agreement significantly expands our distribution network."

 

PJ Ruflin, VP Business Development, Sunset Healthcare Solutions, stated:

 

"Sunset Healthcare Solutions is committed to finding great products and partners to support our customers and their patients. Our partnership with Belluscura offers a unique opportunity to bring meaningful innovation and support to the market at a critical time."

 

Bob Fary, Senior Vice President of Global Sales, commented:

 

"Konstantin has been a tremendous asset since joining Belluscura, as demonstrated by his ability to bring on partners like Sunset Healthcare Solutions. In his new role as VP of North America, Konstantin is set to further drive Belluscura's mission of enhancing patient quality of life through innovative, accessible healthcare solutions. We look forward to building on our success to date as we launch our next generation molecular sieve technology and DISCOV-R."

 

END

 

For further information, please contact:

 

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via MHP

Simon Neicheril, Chief Financial Officer

SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

MHP Communications (Financial PR and Investor Relations)

Tel: +44 (0)20 3128 8100 / +44 7884 494112

Katie Hunt / Matthew Taylor

Email: belluscura@mhpgroup.com

 

 

About Belluscura plc ( www.belluscura.com )

Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGREAEAAFDKLEAA
Date   Source Headline
10th Oct 20234:19 pmRNSForm 8.3 - TMT Acquisition PLC
10th Oct 20233:54 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:52 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:47 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:42 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:28 pmGNWForm 8.3 - Belluscura PLC
9th Oct 20236:11 pmRNSForm 8.3 - Belluscura Plc
9th Oct 20232:32 pmRNSForm 8.3 - Belluscura PLC
9th Oct 20231:39 pmRNSRule 2.9 Announcement
9th Oct 20238:10 amRNSRule 2.9 Announcement
6th Oct 202312:48 pmRNSConditional Allotment and Issue of Placing
5th Oct 20234:49 pmRNSForm 8.3 - Belluscura PLC
3rd Oct 20236:28 pmRNSReplacement - Placing of Unsecured CLNs
3rd Oct 20231:53 pmRNSDirectorate Change
3rd Oct 20231:38 pmRNSPlacing of Unsecured Convertible Loan Notes
3rd Oct 20231:30 pmRNSStatement re Possible Offer
3rd Oct 20231:30 pmRNSStatement regarding possible offer
26th Sep 20237:00 amRNSBelluscura Receives Approval in Hong Kong
14th Sep 20234:26 pmRNSResult of AGM
13th Sep 20237:00 amRNSHalf-year Report
30th Aug 20237:00 amRNSBelluscura Enters Exclusive License Agreement
16th Aug 20237:00 amRNSOrders for over 6,500 DISCOV-R™ received
1st Aug 20237:00 amRNSBelluscura Signs Distribution Agreement
12th Jul 20237:00 amRNSNotice of AGM and Annual Report 2022
29th Jun 20237:00 amRNSBelluscura Commences Premarket Launch of DISCOV-R™
29th Jun 20237:00 amRNSFinal Results for the year ended 31 December 2022
15th Jun 20237:00 amRNSShare allotment; Director/PDMR Shareholding; Appt.
14th Jun 202312:28 pmRNSResult of General Meeting
1st Jun 20237:00 amRNSResult of Retail Offer
26th May 20237:00 amRNSProposed Board Appointment
25th May 202311:15 amRNSRetail Offer to raise up to £0.5m
25th May 202311:00 amRNSProposed Placing and Subscriptions to raise £3.0m
28th Apr 20237:00 amRNSAdditional Broker Option - Extension
20th Apr 20238:19 amRNSExercise of Warrants and Total Voting Rights
3rd Apr 20237:00 amRNSBelluscura begins manufacturing in China
30th Mar 20237:00 amRNSChange of Auditor
24th Feb 20237:00 amRNSBelluscura POC now marketed through GoodRx®
16th Feb 202311:59 amRNSResult of General Meeting
10th Feb 20237:00 amRNSResult of Broker Option
31st Jan 20233:41 pmRNSPosting of Circular
27th Jan 20232:00 pmRNSPrice Monitoring Extension
27th Jan 202312:41 pmRNSPlacing of Unsecured Convertible Loan Notes
24th Jan 20234:40 pmRNSSecond Price Monitoring Extn
24th Jan 20234:35 pmRNSPrice Monitoring Extension
16th Jan 20237:00 amRNSBelluscura appoints Senior VP of Global Sales
13th Jan 20237:00 amRNSYear-end Trading Update
11th Jan 20234:40 pmRNSSecond Price Monitoring Extn
11th Jan 20234:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.